• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

KemPharm inks Apadaz licensing deal with KVK Tech

October 31, 2018 By Fink Densford

KemPharm, KVK Tech

KemPharm (NSDQ:KMPH) said yesterday it inked a collaborative licensing deal with KVK Tech to obtain U.S. commercial rights to the company’s FDA-approved Apadaz drug.

Through the agreement, KemPharm is eligible to receive approximately $3.4 million in pre-launch payments and core cost reimbursement, including a $2 million milestone payment “related to the initial formulary adoption of Apadaz. The deal also includes an aggregate of up to $53 million in milestone payments related to net sales levels.

Net profits from the deal will be shared between KemPharm and KVK up to 50%, depending on net sales level achievements, KemPharm said. KVK will maintain exclusive rights for all commercial, manufacturing, packaging and distribution activities for Apadaz in the US and will be responsible for regulatory and commercialization-related expenses.

The cost of pre-launch expenses including API cost and other material manufacturing, as well as validation batches, inventory investments and launch-specific costs, will shift from KemPharm to KVK, the companies said.

“Securing this agreement with KVK is an important step forward toward the commercial launch of Apadaz, a product which we believe offers a differentiated treatment option for the short-term management of acute pain. We believe Apadaz is now well-positioned for commercial launch since this agreement puts significant manufacturing and distribution capabilities in place and opens the door to further discussions with payers regarding the utilization of Apadaz in their health plans. As one would expect, KVK undertook extensive due diligence and conducted its own market research regarding KemPharm’s proposed commercial plan for Apadaz through its existing relationships with various PBM’s and MCO’s.  We both agree there appears to be a substantial market opportunity for the replacement of current hydrocodone/acetaminophen products with Apadaz. Additionally, as a result of our collaboration, KemPharm has the opportunity to gain greater financial flexibility because of the pre-launch payments, cost-sharing, reimbursements and potential revenue stream from both sales milestones and profit share on a go-forward basis.  We are extremely pleased with this opportunity to partner with KVK for the commercial launch of Apadaz,” KemPharm prez & CEO Travis Mickle said in a press release.

“Since our founding, KVK Tech has strived to become a trusted leader in generics manufacturing and distribution. Our business philosophy is built on a commitment to excellence with a focus on three core values:  Safety, GMP Compliance, and Productivity.  We have built a reputation of providing quality products on-time, even when other manufacturers experience supply disruptions.  Apadaz represents an excellent opportunity to provide physicians and patients with a more differentiated product than currently available on the market today, and we look forward to using our expertise, together with KemPharm, to successfully launch Apadaz,” KVK Tech prez & CEO Anthony Tabasso said in a prepared statement.

Filed Under: Business/Financial News, Featured, Pharmaceuticals Tagged With: kempharm, kvktech

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS